Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study
Table 1
Baseline clin1ical characteristics of patients who completed the study.
UC group
IC group
P value
22
19
Age (years)
61.3 (9.8)
59.1 (15.6)
0.6
Men (%)
59
79
0.2
BMI (kg/m2)
26.5 (3.5)
26.4 (4.1)
0.7
Previous transplant (%)
33
16
0.4
Time on dialysis (months)
50 (48)
50 (45)
0.6
Dialysis time (hours/week)
11.4 (0.9)
11.7 (0.5)
0.3
Calcium dialysate (mmol/L)
1.59 (0.91)
1.53 (0.84)
0.8
iPTH baseline
419 (275; 548)
417 (352; 622)
0.5
Cinacalcet dose (mg/d)
31.6 (13.4)
42.0 (20.8)
0.1
Cinacalcet taking adherence
93.7 (3.3)
84.4 (5.4)
0.1
PO4-chelators ()
1.1 (0.6)
1.2 (1.2)
0.7
Active Vit. D3 (calcitriol) (mcg/week)
1 (0.3)
1.3 (0.5)
0.7
Active Vit. D3 (paricalcitol) (mcg/week)
0
6 (3)
<0.05
Inactive Vit. D3 (UI/week)
2179 (4078)
1597 (3351)
0.5
Values are expressed as mean (standard deviations) or median (25th; 75th percentile) as appropriate.
